ArticleClinical and experimental nephrology2016
Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction.
Article in Clinical and experimental nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Urinary β2-microglobulin as a Potential Biomarker for Early Treatment Selection: A Patient with Severe IgG4-related Tubulointerstitial Nephritis.Internal medicine (Tokyo, Japan) · 2026Article
- Clinical phenotypes and prognosis of IgG4-related diseases accompanied by deteriorated kidney function: a retrospective study.Clinical rheumatology · 2024Article
- Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan.Kidney international reports · 2024Article
- Clinicopathological Patterns and Predictors of the Functional Restoration of Immunoglobulin G4-Related Kidney Disease: A Chinese Single-Center Cohort Study.Frontiers in medicine · 2021Article
- Renal Involvement in IgG4-Related Disease: From Sunlight to Twilight.Frontiers in medicine · 2021Article
- Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement.Immunologic research · 2020Article
- Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan.Arthritis research & therapy · 2020Article
- Low-density lipoprotein apheresis for PLA2R-related membranous glomerulonephritis accompanied by IgG4-related tubulointerstitial nephritis.CEN case reports · 2020Article
- IgG4-related acute interstitial nephritis and the potential role of mCRP autoantibodies: a case report.Renal failure · 2019Article
- A 36-Year-Old Man With Renal Failure, Fever, and Hypocomplementemia.Arthritis care & research · 2019Article
- A case of IgG4-related kidney disease with predominantly unilateral renal atrophy.CEN case reports · 2019Article
- Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.Scientific reports · 2018Article
- Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy.Oncotarget · 2018Article
- Immunoglobulin G4-related kidney diseases: An updated review.World journal of nephrology · 2018Review
- Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study.Arthritis research & therapy · 2016Article
- Recognizing IgG4-related tubulointerstitial nephritis.Canadian journal of kidney health and disease · 2016Review
- Coexistence of Acute Crescent Glomerulonephritis and IgG4-Related Kidney Disease.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough renal dysfunction in IgG4-related kidney disease (IgG4-RKD) shows rapid resolution with glucocorticoid therapy, little is known about the appropriate initial glucocorticoid dose for induction therapy or long-term renal outcome.
methodsWe retrospectively examined the differences in recovery of renal function according to the dose of glucocorticoid used for induction therapy and the long-term renal outcome in 43 patients with definite IgG4-RKD (mostly IgG4-tubulointerstitial nephritis), in whom the estimated glomerular filtration rate (eGFR) before glucocorticoid therapy was <60 ml/min.
resultsMost patients were treated with glucocorticoid alone and had been maintained on glucocorticoid. The initial dose of prednisolone employed was ≤0.6 mg/kg/day (mean 0.47) in 27 patients (group L), and >0.6 mg/kg/day (mean 0.81) in 16 patients (group H). In both groups, the pretreatment eGFR was significantly improved at 1 month after the start of glucocorticoid therapy and the degree of improvement showed no significant inter-group difference. Relapse of IgG4-RKD occurred in 16.7% of the group L patients and 13.3% of the group H patients (p = 0.78). Among 29 patients who were followed up for over 36 months (mean 74 months) and had been maintained on glucocorticoid, none showed progression to end-stage renal disease and there was no significant difference between eGFR at 1 month after treatment and eGFR at the last review.
conclusionIn glucocorticoid monotherapy for IgG4-RKD, a moderate dose is sufficient for induction, and recovery of renal function can be maintained for a long period on low-dose maintenance, although relapse can occur even in patients receiving maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.